GILDライブシグナル | Getagraph.comで利益を最大化

売る 2947 min ago

@ $65.75

発行日: 27 4月 2024 @ 03:36

リターン: -0.49%

前回のシグナル: 4月 26 - 23:48

前回のシグナル: 買う

リターン: 1.07 %

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally...

Stats
本日の出来高	12.35M
平均出来高	7.43M
時価総額	81.58B
EPS	$0 ( 2024-04-25 )
Last Dividend	$0.750 ( 2023-12-14 )
Next Dividend	$0 ( N/A )
P/E	14.54
ATR14	$1.711 (2.61%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Telman Deborah H	Sell	515	Restricted Stock Unit
2024-04-25	Telman Deborah H	Buy	515	Common Stock
2024-04-25	Telman Deborah H	Sell	158	Common Stock
2024-04-01	Parsey Merdad	Sell	2 000	Common Stock
2024-03-28	Lofton Kevin E	Buy	34	Phantom Stock

INSIDER POWER
62.12
Last 99 transactions
Buy: 1 291 503 \| Sell: 311 301

ボリューム相関

長: -0.50 (weak negative)

短: 0.62 (weak)

Signal:(39) Neutral

Gilead Sciences Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Gilead Sciences Inc 相関 - 通貨/商品

0.06
( neutral )

0.26
( neutral )

0.00
( neutral )

0.32
( neutral )

0.37
( neutral )

-0.33
( neutral )

Gilead Sciences Inc 財務諸表

Annual	2023
収益:	$27.12B
総利益:	$21.15B (77.99 %)
EPS:	$4.54

FY	2023
収益:	$27.12B
総利益:	$21.15B (77.99 %)
EPS:	$4.54

FY	2022
収益:	$27.28B
総利益:	$21.62B (79.26 %)
EPS:	$3.66

FY	2021
収益:	$27.31B
総利益:	$20.70B (75.82 %)
EPS:	$4.96

Financial Reports:

No articles found.

Gilead Sciences Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.730 (N/A)	$0.730 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Gilead Sciences Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.47 - average (49.38%) | Divividend Growth Potential Score: 6.34 - Stable (26.81%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.430	2015-06-12
Last Dividend	$0.750	2023-12-14
Next Dividend	$0	N/A
Payout Date	2023-12-28
Next Payout Date	N/A
# dividends	35	--
Total Paid Out	$21.49	--
Avg. Dividend % Per Year	2.65%	--
Score	4.68	--
Div. Sustainability Score	5.47
Div.Growth Potential Score	6.34
Div. Directional Score	5.90	--

Next Divdend (Est)
(2024-07-01)

$0.764 Estimate 39.70 %

Dividend Stability

0.79 Good

Dividend Score

4.68

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2015	$1.290	1.36%
2016	$1.840	1.88%
2017	$2.08	2.80%
2018	$2.28	3.08%
2019	$2.52	3.97%
2020	$2.72	4.17%
2021	$2.84	4.72%
2022	$2.92	4.02%
2023	$3.00	3.51%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0176	1.500	9.65	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00860	1.200	9.71	10.00	[0 - 0.3]
returnOnEquityTTM	0.0232	1.500	-0.854	-1.280	[0.1 - 1]
payoutRatioTTM	5.87	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.980	0.800	-0.102	-0.0814	[1 - 3]
quickRatioTTM	0.721	0.800	-0.463	-0.371	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	9.53	1.000	7.58	7.58	[3 - 30]
operatingCashFlowPerShareTTM	6.80	2.00	7.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.42	2.00	6.79	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.777	1.000	0.382	0.382	[0.2 - 0.8]
operatingProfitMarginTTM	0.336	1.000	5.28	5.28	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.488	0.800	-0.0824	-0.0659	[0.5 - 2]
Total Score				5.47

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	168.55	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0232	2.50	-0.549	-1.280	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.42	2.00	7.86	10.00	[0 - 30]
dividendYielPercentageTTM	4.62	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.80	2.00	7.73	10.00	[0 - 30]
payoutRatioTTM	5.87	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.570	1.500	9.53	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.309	1.000	4.78	0	[0.1 - 0.5]
Total Score				6.34

Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.